#USA #Karyopharm #Newton #Myelofibrosis #Selinexor

Karyopharm's Significant Presentations at ASH 2026

Karyopharm Therapeutics Inc. (Nasdaq: KPTI) is excited to announce that it will present crucial data regarding its innovative cancer treatment, selinexor, during the 68th American Society of Hematology (ASH) Annual Meeting and Exposition. This year's event promises to feature significant findings from two prominent clinical trials focusing on myelofibrosis, alongside an evaluation of selinexor's efficacy in treating multiple myeloma.

Key Highlights from the 2026 ASH Meeting

The preliminary data being showcased originates from the Phase 3 SENTRY trial and the Phase 2 SENTRY-2 trial. These findings are expected to shed light on the potential of selinexor as a viable treatment option for patients battling these complex blood cancers. The oral presentations are scheduled to take place as follows:

1. Phase 3 SENTRY Trial Results on Myelofibrosis
Title: Updated Results Examining Selinexor and Ruxolitinib Combinations in JAK Inhibitor-Naïve Myelofibrosis.
Presentation Timing: December 13, 2026, from 10:15 a.m. CT to 10:30 a.m. CT.
Publication Number: 526

2. Phase 2 SENTRY-2 Final Findings
Title: Monotherapy Study of Selinexor in JAK Inhibitor-Naïve Myelofibrosis Patients.
Presentation Timing: December 12, 2026, from 2:45 p.m. CT to 3:00 p.m. CT.
Publication Number: 244

Additionally, an abstract examining selinexor in conjunction with other therapies for multiple myeloma will be presented as a poster.

Insights from Karyopharm Leadership

Dr. Reshma Rangwala, Karyopharm's Chief Medical Officer, has expressed optimism regarding the trial results. "New data from the SENTRY trial clearly depicts encouraging clinical activity through the use of selinexor combined with ruxolitinib for patients suffering from myelofibrosis, with continued benefits noted as we progressed through week 48," Dr. Rangwala shared. She also highlighted the promising results from the SENTRY-2 trial, which evaluates selinexor as a standalone therapy, suggesting substantial efficacy among patients who had not previously received JAK inhibitors.

About Myelofibrosis and Selinexor

Myelofibrosis is a rare form of blood cancer that creates significant issues in blood cell production due to fibrosis within the bone marrow. Manifestations include splenomegaly and severe anemia, both leading to debilitating symptoms like fatigue and weakness. The primary treatment options available today are JAK inhibitors, with Karyopharm's selinexor representing a groundbreaking alternative aimed at further enhancing patient outcomes.

Selinexor, branded as XPOVIO®, operates as an oral exportin 1 (XPO1) inhibitor, targeting the fundamental mechanism behind cellular function degradation in cancer. Approved in various therapies for multiple myeloma, Karyopharm is committed to expanding its application base, advancing clinical trials, and striving towards innovative solutions for hematologic cancers.

Looking Ahead at Karyopharm

As Karyopharm prepares to unveil more data about selinexor's efficacy, the industry remains hopeful for advancements that could vastly improve the quality of life for patients grappling with myelofibrosis and multiple myeloma. The forthcoming presentations at ASH 2026 are just a glimpse of what Karyopharm aims to achieve in its pursuit of groundbreaking treatments.

This assembly of groundbreaking research exemplifies the growth of innovative healthcare solutions and Karyopharm's steadfast commitment to pioneering therapies that address significant medical needs in oncology. For further details on Karyopharm's products and ongoing trials, visit their official website or reach out to their medical information department.